Orchestra BioMed Holdings Inc. Ordinary Shares (OBIO)
Stock · NASDAQ · Health Care
$5.44as of 10/16/2026
Price chart
Active signals
OBIO Signal Track Record
How signals performed across all stocks →What OBIO's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 40 | -0.9% | 45% | September 18, 2026 |
| Bollinger Band Breakout | 26 | -1.0% | 46% | September 11, 2026 |
| Bollinger Band BreakdownActive now | 19 | +2.8% | 68% | May 15, 2026 |
| 200-Day Moving Average TouchActive now | 17 | -7.4% | 41% | August 6, 2026 |
| Any 20-session window (baseline) | -0.3% | 49% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About OBIO
Orchestra BioMed Holdings, Inc. operates as a biomedical company in the United States. The company's flagship product candidates include Atrioventricular Interval Modulation, a bioelectronic therapy candidate designed to immediately, substantially, and persistently lower blood pressure; and Virtue Sirolimus AngioInfusion Balloon for the treatment of atherosclerotic artery disease. It also develops Cardiac Neuromodula…
- Sector
- Health Care
- Industry
- Medicinal Chemicals and Botanical Products
- Employees
- 86
- Website
- www.orchestrabiomed.com
Fundamentals
- 1-day range
- $5.42$5.87
- Market cap
- $248.50M
- P/E (trailing)
- —
- P/E (forward)
- -3.65
- EPS (trailing)
- $-1.00
- Dividend yield
- —
- Beta
- 0.55
- Avg. volume
- 300.3K
How Orchestra BioMed Holdings Inc. Ordinary Shares Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Mar 12, 2026 · via SEC EDGAR / Finnhub
Forecasts
7 analyst ratings
Orchestra BioMed Holdings Inc. Ordinary Shares Competitors
Chosen by industry and closest market cap.
- OBIOOrchestra BioMed Holdings Inc. Ordinary Shares$5.45▼ 5.05%Market cap $248.50MP/E —$3.1$6.5
- NAGENiagen Bioscience Inc. Common Stock$2.49▼ 3.49%Market cap $240.54MP/E 12.74$2.51$7.95
- USNAUSANA Health Sciences Inc. Common Stock$15.54▲ 1.04%Market cap $274.91MP/E 32.28$12.57$23.59
- SNDLSNDL Inc. Common Shares$1.25▲ 3.31%Market cap $312.36MP/E —$1.13$2.57
- ACBAurora Cannabis Inc. Common Shares$3.99▼ 2.68%Market cap $184.63MP/E —$3.59$8.75
- MDWDMediWound Ltd. Ordinary Shares$11.85▼ 2.95%Market cap $183.44MP/E —$11.9$20.03
- CGCCanopy Growth Corporation Common Shares$0.713▼ 3.13%Market cap $400.49MP/E —$0.995$3.28
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| OBIO Orchestra BioMed Holdings Inc. Ordinary Shares | $248.50M | — | $5.45 | ▼ 5.05% | $3.1$6.5 |
| NAGE Niagen Bioscience Inc. Common Stock | $240.54M | 12.74 | $2.49 | ▼ 3.49% | $2.51$7.95 |
| USNA USANA Health Sciences Inc. Common Stock | $274.91M | 32.28 | $15.54 | ▲ 1.04% | $12.57$23.59 |
| SNDL SNDL Inc. Common Shares | $312.36M | — | $1.25 | ▲ 3.31% | $1.13$2.57 |
| ACB Aurora Cannabis Inc. Common Shares | $184.63M | — | $3.99 | ▼ 2.68% | $3.59$8.75 |
| MDWD MediWound Ltd. Ordinary Shares | $183.44M | — | $11.85 | ▼ 2.95% | $11.9$20.03 |
| CGC Canopy Growth Corporation Common Shares | $400.49M | — | $0.713 | ▼ 3.13% | $0.995$3.28 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Orchestra BioMed Exceeds Full Enrollment Target in the BACKBEAT Global Pivotal Trial of AVIM TherapyYahoo · 10/1/2026
- Strength Seen in Orchestra BioMed Holdings, Inc. (OBIO): Can Its 5.2% Jump Turn into More Strength?Yahoo · 9/21/2026
- Orchestra BioMed Announces AVIM Therapy to Be Featured in Two Sessions at HRX Live 2026Yahoo · 9/16/2026
- Orchestra BioMed Receives $6.1 Million Milestone Payment from Acquisition of Vivasure by HaemoneticsYahoo · 9/15/2026
- This Copart Analyst Turns Bullish; Here Are Top 2 Upgrades For FridayBenzinga · 9/11/2026
Insider Activity
Insider Actions →- Sherman Darren · October 1, 2026 · Sale15.0K @ $6.36
- Hochman David P · September 10, 2026 · Tax Withholding3.3K @ $5.81
- Hochman David P · September 3, 2026 · Buy10.0K @ $4.79
- Sherman Darren · September 1, 2026 · Sale15.0K @ $4.94
- Aiello Joshua · August 26, 2026 · Tax Withholding203 @ $5.26
- Taylor Andrew Lawrence · August 26, 2026 · Tax Withholding3.1K @ $5.26
- Sherman Darren · August 26, 2026 · Buy2.0K @ $5.33
- Sherman Darren · August 26, 2026 · Tax Withholding4.9K @ $5.26
- Mack John Prosper · August 12, 2026 · Tax Withholding4.9K @ $4.42
- Cleary Chris · August 12, 2026 · Tax Withholding4.2K @ $4.42
- Pacitti David · August 12, 2026 · Tax Withholding3.8K @ $4.42
- Fain Eric S · August 12, 2026 · Tax Withholding5.1K @ $4.42
- Sherman Darren · August 3, 2026 · Sale15.0K @ $4.09
- Sherman Darren · July 1, 2026 · Sale15.0K @ $4.27
- Cleary Chris · June 24, 2026 · Tax Withholding3.5K
Institutional Ownership
March 31, 2026
- Total shares held
- 22.86M
- Total value held
- $96.97M
- Institutional holders
- 62
- Unknown8.31M
- Unknown5.04M
- Unknown2.20M
- Unknown1.00M
- Unknown896.7K
- Unknown702.5K
- Unknown635.7K
- Unknown485.5K
- Unknown402.6K
- Unknown265.5K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
OBIO Shares Rise 5.2% Amid Positive Momentum
Orchestra BioMed Holdings (OBIO) shares recently increased by 5.2%, a move that some observers see as a sign of strengthening momentum. The stock currently trades within its 52-week range of $2.20 to $6.48. Analysts maintain an average price target of $12.14, suggesting a significant gap between the current market price and professional estimates.
OBIO Shares Rise 5.2% Amid Positive Momentum. Orchestra BioMed Holdings (OBIO) shares recently increased by 5.2%, a move that some observers see as a sign of strengthening momentum. The stock currently trades within its 52-week range of $2.20 to $6.48. Analysts maintain an average price target of $12.14, suggesting a significant gap between the current market price and professional estimates.